JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

161

Participants

Timeline

Start Date

November 21, 2021

Primary Completion Date

May 17, 2023

Study Completion Date

November 21, 2026

Conditions

Local Advanced or Metastatic NSCLCHarboring EGFR Common Mutation

Interventions

DRUG

JMT101 Injection

JMT101 Injection, 6 mg/kg intravenously, over 90 mins every 14 or 21 days

DRUG

Osimertinib tablet

Osimertinib 80 or 160mg po everyday

Trial Locations (1)

Li Zhang, Beijing

All Listed Sponsors

lead

Shanghai JMT-Bio Inc.

INDUSTRY